High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - Results of a comprehensive meta-analysis

Cancer Treatment Reviews

Volumn 33, Issue 4, 2007, Pages 338-346

  Greb, Alexander ^a   Bohlius, Julia ^a   Trelle, Sven ^a   Schiefer, Daniel ^b   De Souza, Carmino A ^c   Gisselbrecht, Christian ^d   Intragumtornchai, Tanin ^e   Kaiser, Ulrich ^f   Kluin Nelemans, Hanneke C ^g   Martelli, Maurizio ^h   Milpied, Noel Jean ⁱ   Santini, Gino ^j   Verdonck, Leo F ^k   Vitolo, Umberto ^l   Schwarzer, Guido ^m   Engert, Andreas ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b KOK Hospital Stuttgart   (Germany)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d SAINT LOUIS HOSPITAL   (France)

^e CHULALONGKORN UNIVERSITY   (Thailand)

^f Department of Hematology   (Germany)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ UNIVERSITÉ DE NANTES   (France)

^j UNIVERSITY OF GENOA   (Italy)

^k UTRECHT UNIVERSITY   (Netherlands)

^l Universitaria San Giovanni Battista   (Italy)

^m UNIVERSITY OF FREIBURG   (Germany)

more..

Author keywords

Autologous transplantation; High dose chemotherapy; Meta analysis; Non Hodgkin's lymphoma; Systematic review

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; BLEOMYCIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; MELPHALAN; MEPREDNISONE; METHOTREXATE; MITOXANTRONE; PREDNISONE; TENIPOSIDE; VINCRISTINE; VINDESINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; HUMAN; MEDLINE; META ANALYSIS; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LYMPHOMA, NON-HODGKIN; RANDOMIZED CONTROLLED TRIALS; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 34249065628     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.02.002     Document Type: Review

References (47)

1. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 235-242
2. Sehn L.H., Donaldson J., Chhanabhai M., et al. Introduction of combined CHOP plus Rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol (2005)
3. Gottlieb J.A., Gutterman J.U., McCredie K.B., et al. Chemotherapy of malignant lymphoma with adriamycin. Cancer Res 33 (1973) 3024-3028
4. McKelvey E.M., Gottlieb J.A., Wilson H.E., et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38 (1976) 1484-1493
5. van Agthoven M., Sonneveld P., Hagenbeek A., et al. A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin's lymphoma. Hematol J 4 (2003) 399-409
6. A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993;329:987-94.
7. Fisher R.I., Gaynor E.R., Dahlberg S., et al. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol 5 Suppl. 2 (1994) 91-95
8. Fisher R.I. Treatment of aggressive non-Hodgkin' lymphomas. Lessons from the past 10 years. Cancer 74 (1994) 2657-2661
9. Jerkeman M., Anderson H., Cavallin-Stahl E., et al. CHOP versus MACOP-B in aggressive lymphoma - a Nordic Lymphoma Group randomised trial. Ann Oncol 10 (1999) 1079-1086
10. Zinzani P.L., Martelli M., Magagnoli M., et al. Anaplastic large cell lymphoma Hodgkin's-like: a randomized trial of ABVD versus MACOP-B with and without radiation therapy. Blood 92 (1998) 790-794
11. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333 (1995) 1540-1545
12. Nademanee A., Schmidt G.M., O'Donnell M.R., et al. High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study. Blood 80 (1992) 1130-1134
13. Freedman A.S., Takvorian T., Neuberg D., et al. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study. J Clin Oncol 11 (1993) 931-936
14. Nademanee A., Molina A., O'Donnell M.R., et al. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group. Blood 90 (1997) 3844-3852
15. Vitolo U., Cortellazzo S., Liberati A.M., et al. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. J Clin Oncol 15 (1997) 491-498
16. Schiefer DH, Greb A, Bohlius J, et al. High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults. (Protocol). The cochrane database of systematic reviews; 2003.
17. Parmar M.K., Torri V., and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17 (1998) 2815-2834
18. Egger M., Davey S.G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. Bmj 315 (1997) 629-634
19. Linch D., Yung L., Smith P., et al. A randomised trial of CHOP × 6-8 vs HOP × 3 + BEAM + ASCT in 457 patients with poor prognosis histologically aggressive non-Hodgkins lymphoma. Ann Oncol 13 Suppl. 2 (2002) 28
20. De Souza C., Baldissera R., Simoes B., et al. Unselected High-Risk IPI NHL presented a high early mortality rate in a prospective randomized study comparing conventional chemotherapy and high-dose escalation followed by autologous bone marrow transplantation. Blood (2001) 319-391 [abstract]
21. Gianni A.M., Bregni M., Siena S., et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336 (1997) 1290-1297
22. Vitolo U, Liberati A, Lambertenghi DG, et al. High dose chemotherapy (HDS) with autologous stem cell transplantation (ASCT) vs intensified chemotherapy MegaCEOP in high risk diffuse large cell lymphoma (DLCL): an update of a multicenter randomized trial by Italian Lymphoma Intergroup (ILI); 2002.
23. Haioun C., Lepage E., Gisselbrecht C., et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 15 (1997) 1131-1137
24. Haioun C., Lepage E., Gisselbrecht C., et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 18 (2000) 3025-3030
25. Intragumtornchai T., Prayoonwiwat W., Numbenjapon T., et al. CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma. Clin Lymphoma 1 (2000) 219-225
26. Gisselbrecht C., Lepage E., Molina T., et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20 (2002) 2472-2479
27. Kaiser U., Uebelacker I., Abel U., et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol 20 (2002) 4413-4419
28. Kluin-Nelemans H.C., Zagonel V., Anastasopoulou A., et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst 93 (2001) 22-30
29. Martelli M., Gherlinzoni F., De Renzo A., et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol 21 (2003) 1255-1262
30. Milpied N., Deconinck E., Gaillard F., et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350 (2004) 1287-1295
31. Verdonck L.F., van Putten W.L., Hagenbeek A., et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332 (1995) 1045-1051
32. Santini G, Olivieri A, Majolino I, et al. VACOP-B vs VACOP-B High-dose sequential therapy (HDS) for aggressive non-Hodgkin's lymphoma (NHL). Final analysis of the NHLCSG; 2003.
33. Rodriguez M.A., van Besien K., Hagemeister F.B., et al. Randomized comparison of frontline alternating chemotherapy (ATT) versus brief induction followed by autologous stem cell transplantation (ASCT) for aggressive lymphomas. Blood 102 (2003) [abstract]
34. Martelli M., Vignetti M., Zinzani P.L., et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study. J Clin Oncol 14 (1996) 534-542
35. Santini G., Salvagno L., Leoni P., et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 16 (1998) 2796-2802
36. Fanin R., Silvestri F., Geromin A., et al. Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas in first complete or partial remission: a retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index. Bone Marrow Transplant 21 (1998) 263-271
37. Cortelazzo S., Rossi A., Bellavita P., et al. Clinical outcome after autologous transplantation in non-Hodgkin's lymphoma patients with high international prognostic index (IPI). Ann Oncol 10 (1999) 427-432
38. Simnett S.J., Stewart L.A., Sweetenham J., et al. Autologous stem cell transplantation for malignancy: a systematic review of the literature. Clin Lab Haematol 22 (2000) 61-72
39. Strehl J., Mey U., Glasmacher A., et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica 88 (2003) 1304-1315
40. Launchbury A.P., and Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 19 (1993) 197-228
41. Jacquy C., Soree A., Lambert F., et al. A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: one-half of patients significantly mobilize malignant cells. Br J Haematol 110 (2000) 631-637
42. Marcus R., Imrie K., Belch A., et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105 (2005) 1417-1423
43. Coiffier B., Haioun C., Ketterer N., et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92 (1998) 1927-1932
44. Vose J.M., Link B.K., Grossbard M.L., et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19 (2001) 389-397
45. Pfreundschuh M., Trumper L., Kloess M., et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104 (2004) 634-641
46. Pfreundschuh M., Trumper L., Kloess M., et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104 (2004) 626-633
47. Tilly H., Lepage E., Coiffier B., et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102 (2003) 4284-4289